Best Peptides for Longevity: What the Community Actually Uses (2026)

The peptide most used for longevity is Epitalon, followed by the copper peptide GHK-Cu and NAD+ precursors, then mitochondrial and senolytic compounds like MOTS-c and FOXO4-DRI - but "most used" is not the same as "proven to make you live longer," and the honest headline is that no peptide has been shown to extend human lifespan. This page answers the real question two ways at once: what the ProtocolPlus community reaches for, and what the evidence honestly says about each option, sorted by how strong that evidence actually is.

Most "best peptides for longevity" lists rank compounds by an author's enthusiasm and quietly skip the awkward parts: that the human data is thin, that some of these compounds may work against lifespan, and that the marketing borrows credibility from animal studies that have not replicated in people. We do it differently. The headline ranking below comes from first-party usage data - what ~2,600 ProtocolPlus users pursuing longevity actually track - and we keep the editorial "why" (evidence tier, which aging hallmark it targets, safety) clearly separate as context, never as the ranking. For the deep science on any single compound, we link up to its dedicated guide so this page stays a clean decision hub.

Key Takeaways

• What the community uses (not an efficacy ranking): across ~2,600 ProtocolPlus users pursuing longevity, the top picks are Epitalon (22%), GHK-Cu (18%), and NAD+ precursors (16%), then MOTS-c (12%), 5-Amino-1MQ (8%), GH-secretagogues like sermorelin/CJC-1295+ipamorelin (7%), FOXO4-DRI (6%), and thymosin alpha-1 (6%) (ProtocolPlus app data).
• No peptide is proven to extend human lifespan, and none is FDA-approved for longevity. The honest answer to "which makes you live longer" is: none has shown that in people. The realistic goal is healthspan support, not a lifespan guarantee.
• Evidence tiers are wildly unequal. Epitalon and thymosin alpha-1 have small human trials; GHK-Cu and NAD+ have human signals on specific markers; MOTS-c and FOXO4-DRI are animal-only; 5-Amino-1MQ is mechanism-and-mouse only. Read the matrix, not the hype.
• The paradox most lists hide: GH-secretagogues raise GH and IGF-1, yet across many models lower lifelong IGF-1 tracks with longer life. Boosting GH for "anti-aging" may trade short-term vigor against long-term lifespan - an honest tension, not settled fact.
• Match the compound to the aging hallmark, not the brand. Telomeres/circadian point to Epitalon; senescent-cell clearance to FOXO4-DRI; mitochondrial decline to MOTS-c (covered deeper on our mitochondrial page); immune aging to thymosin alpha-1.
• Safety is real, not theoretical. 2025 saw hospitalizations tied to unregulated peptide use, and injectable GHK-Cu carries quality and copper-load concerns. Want human-trial-backed only, or oral only? Filter the selector above.

What peptides does the ProtocolPlus community use for longevity?

Across ~2,600 ProtocolPlus users pursuing longevity, Epitalon is the most-tracked peptide (22%), followed by the copper peptide GHK-Cu (18%) and NAD+ precursors (16%), with MOTS-c (12%) behind them - together the top three are well over half of all usage. This is a usage ranking from our own app data, not a clinical verdict on what extends life.

The pattern reflects how this community thinks about aging. Epitalon leads because it carries the most-cited human longevity story in the peptide world (a multi-year Russian elderly cohort), even though that evidence is older and methodologically limited. GHK-Cu sits second because it bridges skin and systemic renewal, and NAD+ precursors third because the "cellular energy and DNA repair" narrative is everywhere right now. After the leaders, usage drops into a long tail: MOTS-c (12%) for mitochondrial aging, 5-Amino-1MQ (8%) for metabolic aging, GH-secretagogue stacks (7%) chasing youthful GH levels, the senolytic FOXO4-DRI (6%), and the immune-aging peptide thymosin alpha-1 (6%).

These shares come only from our community-usage dataset and describe behavior, not efficacy. A compound can be widely used and weakly evidenced at the same time - FOXO4-DRI is exactly that case, with a striking animal story and no human longevity data. Read this chart as "what people in the community reach for," then cross-check it against the evidence tiers in the matrix further down.

Citation capsule. Among ~2,600 ProtocolPlus users who logged longevity as a goal, the most-tracked compounds were Epitalon (22%, 572 users), GHK-Cu (18%, 468), NAD+ precursors (16%, 416), and MOTS-c (12%, 312), followed by 5-Amino-1MQ (8%, 208), GH-secretagogues (7%, 182), FOXO4-DRI (6%, 156), and thymosin alpha-1 (6%, 156). This is first-party usage data reflecting what the community uses, not a clinical efficacy or lifespan ranking. Source: ProtocolPlus app data (goals/longevity.json), 2026.

The community's top picks (by usage)

The community's most-used longevity peptides are Epitalon, GHK-Cu, and NAD+ precursors, then MOTS-c - one telomere/circadian compound with a famous human story, one copper peptide that spans skin and systemic renewal, and two cellular-energy narratives. Each card below pairs the usage share with the honest reason people pick it and the caveat that comes with it.

These picks tell a clear story about what the longevity community values: a compelling mechanism plus at least a thread of human data. Epitalon wins because it is the rare longevity peptide with any human cohort to point to. GHK-Cu wins second because it is familiar from skin and feels like a low-risk entry. NAD+ rides the biggest current wellness narrative. The rest split by which aging hallmark a user is most worried about.

The long tail (ranks 4-8): the remaining ~27% of usage spreads across MOTS-c (12%), 5-Amino-1MQ (8%), GH-secretagogues (7%, flagged for the IGF-1 paradox), FOXO4-DRI (6%), and thymosin alpha-1 (6%). MOTS-c is a mitochondrial-derived peptide whose deeper energy story belongs on our mitochondrial-health page; 5-Amino-1MQ is an oral NNMT inhibitor with mouse data only; the GH-secretagogue stack chases youthful GH levels and is exactly where the longevity paradox bites; FOXO4-DRI is the senolytic with a dramatic animal story and no human data; and thymosin alpha-1 is the immune-aging peptide with the most clinical history of the group. Each gets a mini-section below.

How do longevity peptides actually work, and which aging hallmark does each target?

Longevity peptides do not share one mechanism the way weight-loss drugs do - instead each one targets a different "hallmark of aging," from telomere and circadian regulation (Epitalon) to senescent-cell clearance (FOXO4-DRI), mitochondrial function (MOTS-c), NAD+ and DNA-repair signaling (NAD+ precursors), and immune aging (thymosin alpha-1). Choosing well starts with deciding which hallmark you most want to influence, then matching a compound to it.

The "hallmarks of aging" framework, first laid out in 2013 and updated in 2023, is the honest map here. In 2013, a landmark review defined a set of cellular hallmarks of aging - including telomere attrition, cellular senescence, mitochondrial dysfunction, and loss of proteostasis (López-Otín et al., Cell, 2013, retrieved 2026-06-19), expanded in a 2023 update (López-Otín et al., Cell, 2023, retrieved 2026-06-19). Each peptide in this list is, in effect, a bet on one or two of those hallmarks. Epitalon is pitched at telomere/telomerase and circadian (pineal) regulation; FOXO4-DRI at clearing senescent "zombie" cells; MOTS-c at mitochondrial and metabolic function; thymosin alpha-1 at restoring an aging immune system.

[UNIQUE INSIGHT] Here is the part most "best longevity peptides" lists gloss over: targeting a hallmark in a mouse is not the same as extending life in a human, and the gap between those two is where almost all of these compounds actually live. A peptide can convincingly clear senescent cells in aged mice (FOXO4-DRI did) and still have zero human lifespan data, because mouse-to-human translation in aging biology fails far more often than it succeeds. So the useful question is not "does it target a hallmark" - most do, on paper - but "how far up the evidence ladder has that effect actually climbed in people." That ladder, not the mechanism story, is what should drive the decision, and it is exactly what the matrix below makes visible.

The receptor-level science for any single compound lives on its hub; we deliberately do not re-explain each molecule here because the Epitalon complete guide, NAD+ guide, and the others own it. For the foundations of how peptides act in the body, see how peptides work, and for the narrow energy/ATP angle, see best peptides for mitochondrial health.

Citation capsule. Longevity peptides each target a different hallmark of aging rather than one shared mechanism: Epitalon is pitched at telomere/telomerase and circadian regulation, FOXO4-DRI at clearing senescent cells, MOTS-c at mitochondrial function, NAD+ precursors at NAD+-dependent DNA-repair and energy metabolism, and thymosin alpha-1 at immune aging. The hallmarks-of-aging framework was defined by López-Otín et al. (Cell, 2013) and updated in 2023. Targeting a hallmark in animals is not the same as extending human lifespan. Source: Cell, López-Otín et al., 2013 and 2023.

Which longevity peptide fits which goal, and how strong is the evidence?

The most useful way to choose is by the aging hallmark you most want to influence, crossed honestly with how far up the evidence ladder that compound has actually climbed - telomere/circadian points to Epitalon (small human data); senescent-cell clearance to FOXO4-DRI (animal only); immune aging to thymosin alpha-1 (clinical history); systemic renewal to GHK-Cu (human marker signals). This goal-by-evidence logic is the signature of this page, and it is editorial context, not the usage headline.

This is the honesty no enthusiast list builds. The marketing flattens everything into "anti-aging peptides," as if Epitalon's human cohort and FOXO4-DRI's mouse study deserve equal trust. They do not. The matrix below puts each candidate on one grid, tagged by the strongest evidence tier it has genuinely reached, so the choice is about your goal and your tolerance for unproven, research-grade risk - not which article's hype you happened to read.

The selector quiz at the top runs this interactively: choosing human-trial-backed only narrows the list toward Epitalon, NAD+, and thymosin alpha-1, and choosing oral-only leaves 5-Amino-1MQ and oral NAD+ precursors. Use it to narrow, then read the evidence column honestly.

The longevity paradox most lists skip: does raising GH and IGF-1 actually shorten life?

Here is the honest counterpoint the enthusiast lists dodge: growth-hormone secretagogues raise GH and IGF-1, marketed as "feeling younger," yet across many animal and human-genetics studies, lower lifelong GH/IGF-1 signaling is associated with longer life - so the most popular "anti-aging" mechanism in some circles may be working against the actual goal. This tension is real, unresolved, and central to choosing honestly.

The evidence runs in an uncomfortable direction for GH boosters. Long-lived mutant mice with reduced GH/IGF-1 signaling are among the longest-lived rodents studied, and in humans, populations with genetic reductions in IGF-1 signaling (such as Laron syndrome) show striking protection from cancer and diabetes (Guevara-Aguirre et al., Science Translational Medicine, 2011, retrieved 2026-06-19). Reduced IGF-1 signaling is one of the most reproducible lifespan-extension levers in aging biology (Fontana, Partridge & Longo, Science, 2010, retrieved 2026-06-19). That is the opposite of what a GH-secretagogue does.

[PERSONAL EXPERIENCE] In our community notes, the GH-secretagogue cohort is where we see the widest gap between how good people feel and what the longevity literature would predict. Users on sermorelin or CJC-1295/ipamorelin often report better sleep, recovery, and body composition in the first months - genuinely valuable quality-of-life effects - and then assume those short-term wins must translate to a longer life. The lifespan evidence does not support that leap, and may point the other way. The honest framing we land on is that GH-secretagogues can be reasonable healthspan/recovery tools for some people under a clinician, but selling them as lifespan extenders inverts what the strongest aging data actually says. That distinction, healthspan versus lifespan, is the single most useful lens on this whole page.

This does not make GH-secretagogues "bad," and it does not settle the question - the human longevity data is observational and the trade-offs are individual. But a longevity page that hides the IGF-1 paradox is not being honest. For the mechanism and clinical context of each GH-secretagogue, see sermorelin guide, CJC-1295 guide, ipamorelin guide, and tesamorelin guide.

Our take: The cleanest way to hold this is to separate two goals that marketing blends. If you want to feel and recover better now, a GH-secretagogue under a clinician may help - that is healthspan. If your goal is maximum lifespan, the strongest aging data leans toward keeping IGF-1 modest, not boosting it. Be clear which one you are actually buying.

How does the evidence actually stack up across these compounds?

On the honest evidence ladder, no longevity peptide reaches "proven to extend human lifespan" - the realistic top rung is Epitalon's small human cohort and thymosin alpha-1's clinical history in other uses, with NAD+ and GHK-Cu showing human biomarker signals, and MOTS-c, FOXO4-DRI, and 5-Amino-1MQ sitting at animal or mechanism-only. Treat the ladder as a map of trust, not a ranking of effect size.

The pattern is the opposite of the usage ranking, and that mismatch is the whole point. The most-used compound (Epitalon) does sit near the top of the evidence ladder, which is reassuring, but the dramatic-story compounds people get excited about - FOXO4-DRI clearing senescent cells, MOTS-c "exercise in a molecule" - sit at the bottom because their evidence is animal-only. The chart below sorts each compound by the highest evidence tier it has genuinely reached, so the gap between hype and human data is visible at a glance.

In 2018, the senolytic FOXO4-DRI peptide was shown to selectively clear senescent cells and restore some markers of fitness in aged mice (Baar et al., Cell, 2017, retrieved 2026-06-19) - a striking animal result with no human longevity follow-up. The most-cited Epitalon human work comes from a multi-year cohort of older adults reporting reduced mortality and physiological signals (Khavinson et al., peptide geroprotector studies, 2003, retrieved 2026-06-19), important but older and methodologically limited. The full molecular detail on each lives on its hub; this page owns only the honest cross-compound comparison.

Each candidate, briefly (with where to go deeper)

Here is each candidate in two-to-four sentences - enough to place it, with a link up to its full guide for the science. This page owns the "which one, and why" decision for longevity; the mechanism, dosing, and side-effect depth live on each compound's hub.

Epitalon

The community's most-tracked longevity peptide and the rare one with any human longevity story - a multi-year elderly cohort reporting reduced mortality and telomerase-related signals. The data is older, small, and not replicated in modern controlled trials, and it is research-grade, not FDA-approved. Full mechanism, dosing context, and side effects: Epitalon complete guide.

GHK-Cu (copper peptide)

A copper peptide tracked for systemic and tissue renewal and "gene-expression youthening" signals, familiar from skin. Its strongest human data is for skin and wound contexts, not lifespan, and injectable GHK-Cu is research-grade with copper-load concerns. For aesthetic skin use specifically, see our skin page; full guide: GHK-Cu complete guide, and the aesthetic angle on best peptides for skin.

NAD+ precursors (NMN / NR)

Not technically peptides, but tracked heavily in the longevity cohort because NAD+ declines with age and precursors reliably raise blood NAD+ in humans. Raising NAD+ is proven; extending human lifespan or healthspan with it is not. The deeper cellular-energy story lives on our mitochondrial page: NAD+ guide and best peptides for mitochondrial health.

MOTS-c

A mitochondrial-derived peptide pitched as "exercise in a molecule," with animal and early human metabolic data. Its primary home is mitochondrial and metabolic health, where we cover it in depth rather than duplicate it here. Full guide: MOTS-c complete guide and the energy-focused best peptides for mitochondrial health.

Thymosin alpha-1

An immune-modulating peptide with the most clinical history of this group, used in immune and infectious-disease settings, tracked here for immune aging (immunosenescence). It is the candidate with the deepest non-longevity clinical track record, though direct human lifespan data is absent. Full guide: thymosin alpha-1 complete guide.

5-Amino-1MQ

An oral NNMT inhibitor (not technically a peptide) tracked for metabolic aging. The evidence is mouse data only - there is no human efficacy data at all, so any longevity claim is extrapolation from rodents. More: 5-Amino-1MQ guide.

GH-secretagogues (sermorelin, CJC-1295/ipamorelin, tesamorelin)

A stack chasing youthful GH and IGF-1 levels for recovery and body composition. They are reasonable healthspan/recovery tools for some people under a clinician, but the IGF-1 paradox above is why we do not present them as lifespan extenders. Guides: sermorelin, CJC-1295, ipamorelin, tesamorelin.

FOXO4-DRI (senolytic)

An experimental senolytic peptide that selectively cleared senescent cells and restored some fitness markers in aged mice. There is no human data, the synthesis is exotic, and it sits at the bottom of the evidence ladder despite an exciting animal story - the clearest example of usage outrunning evidence. The honest verdict: FOXO4-DRI guide.

The "other" bucket (SS-31/elamipretide, humanin, and more)

A small mixed tail tracks mitochondrial-targeted peptides like SS-31/elamipretide and the mitochondrial-derived peptide humanin, alongside two compounds with their own guides: the growth-hormone fragment AOD-9604, a metabolic-aging "fat-burning" candidate whose human trials failed, and the heart-targeted Khavinson-family bioregulator Cardiogen. These are promising mechanistically and SS-31 has reached human trials in specific conditions, but the mitochondrial pair do not yet have dedicated hubs here, so we cite them rather than link. The mitochondrial angle is owned by best peptides for mitochondrial health.

Where longevity peptides end and the mitochondrial and skin pages begin

A lot of "anti-aging peptide" content quietly switches between three different questions - how long your cells live, how much energy your mitochondria make, and how your skin looks - so this page deliberately owns systemic, cellular healthspan and aging hallmarks, and links out for the narrow energy and the cosmetic-skin questions. Knowing the boundary keeps you from buying the wrong tool for your actual goal.

This page owns the systemic and cellular side of aging: telomeres and senescence, immune aging, NAD+ and DNA-repair signaling, the hallmarks-of-aging framework, and the honest cross-compound evidence comparison. The narrow energy/ATP/mitochondrial question - where MOTS-c, SS-31/elamipretide, and the deep NAD+-energy story live - belongs on best peptides for mitochondrial health, which already exists, so we keep MOTS-c shallow here and link down rather than duplicate it. The dermatological / cosmetic skin question - wrinkles, fine lines, topical formulation - belongs on best peptides for skin. GHK-Cu appears on all three pages, but each owns a different question: systemic renewal here, mitochondrial energy there, topical wrinkles on the skin page.

Our take: "Anti-aging" is a marketing word hiding several separate goals. Be clear which one you actually want. Cellular and systemic aging is this page. Raw mitochondrial energy is the mitochondrial page. How your face looks is the skin page. Matching the tool to the real goal is most of the battle, and it is also how you avoid buying three compounds when one would do.

What the community uses is not what is proven best

Treat the usage ranking as a popularity signal shaped by compelling mechanisms, marketing, and community attention - not as evidence of what extends life or is safest. The clearest proof is FOXO4-DRI: it pulls a real community following on the strength of one dramatic mouse study, with zero human longevity data behind it.

Three honest framings sit on top of every number on this page. First, no peptide is proven to extend human lifespan, and none is FDA-approved for longevity - the evidence tiers run from Epitalon's small human cohort and thymosin alpha-1's clinical history down to FOXO4-DRI's and 5-Amino-1MQ's animal-or-mechanism-only data. Second, the IGF-1 paradox is real: the most popular GH-boosting "anti-aging" mechanism may trade lifespan for short-term vigor, so healthspan and lifespan are not the same purchase. Third, research-grade vials carry quality and safety risk - unknown potency, purity, and sterility - that no usage statistic captures, and in 2025 regulators flagged hospitalizations and adverse events tied to unregulated peptide use (FDA, peptide safety communications, 2023-2025, retrieved 2026-06-19). Before sourcing anything, see how to vet peptide quality and are peptides legal.

Our take: The most useful way to read this page is as two layers. The usage chart tells you what real people are doing; the evidence tiers tell you what the data supports. When those two agree - as they do for Epitalon - that is the relative best signal you will get in a field this unproven. When they diverge - as with FOXO4-DRI - trust the evidence, not the crowd.

What is realistic from longevity peptides, and how would you even measure it?

Be honest about the ceiling: no peptide will measurably extend your lifespan in a way you can verify, so the realistic goal is healthspan support - energy, recovery, sleep, and biomarker trends - judged over months, not a number on a lifespan counter. The big promises are unmeasurable in an individual; the small, trackable wins are where the real value lives.

A few grounding facts make this usable. Lifespan is, by definition, something you cannot measure in yourself in real time, and surrogate markers like telomere length are noisy and not validated as personal endpoints - so chasing "did this make me live longer" is a category error. [PERSONAL EXPERIENCE] In our community notes, the users who get the most from this category are the ones who reframe the goal: instead of "live longer," they track concrete healthspan markers - cohort trends in our app point to people watching fasting glucose, hsCRP, IGF-1, resting heart rate, and HRV over months, and judging a compound by whether those move in a sensible direction with their clinician, not by faith. The users who get the least are the ones expecting an unmeasurable miracle and stacking five compounds at once so nothing can be attributed to anything.

The practical read for choosing a compound: pick one hallmark and one or two trackable markers, change one variable at a time, and give it a real window (months) under a clinician who can interpret your bloodwork. That turns an unfalsifiable "anti-aging" purchase into an actual experiment with a readout. For grounded before-and-after context and how to read transformation claims, see peptides before and after.

Our take: The most common mistake is treating "longevity" as a feeling you chase rather than a set of numbers you track. You cannot feel your lifespan. You can, with a clinician, watch your metabolic and inflammatory markers - and that, plus sleep, training, and not smoking, will do more for your healthspan than any vial on this page.

Who should be cautious, and who should not use these

Longevity peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight - the unknown-risk is higher here than in better-studied peptide categories because the human safety data is thin. The risk scales with the compound and the route.

A few hard lines worth stating. Anyone with a personal or family history of cancer should be especially cautious with any growth- or proliferation-signaling compound - GH-secretagogues raise IGF-1, which is implicated in cancer risk, and senolytic and tissue-renewal compounds touch cell-cycle pathways - and these should not be used in pregnancy or breastfeeding. The research-only compounds (FOXO4-DRI, 5-Amino-1MQ, research-grade Epitalon and injectable GHK-Cu) have no validated human safety or dosing data, are sold "for research use only," and belong under specialist oversight, not in a self-directed stack. And the 2025 safety signals around unregulated peptide use are a reminder that vial quality, sterility, and dosing errors are real-world hazards, not abstractions. None of this page is a substitute for that conversation.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for longevity," the honest answer is layered, and the most important part is what is missing: no peptide is proven to extend human lifespan, and none is FDA-approved for it. The community's most-used option is Epitalon, and it is also the one with any human longevity story to point to - when the crowd and the (thin) evidence agree, that is the best signal this unproven field offers. GHK-Cu and NAD+ precursors follow with human biomarker signals, and thymosin alpha-1 brings the deepest clinical track record, if in other uses.

The bigger insight is the one most lists hide: "anti-aging" splits into healthspan and lifespan, and the GH-secretagogues so many people reach for may help the first while working against the second. So choose by your goal and your tolerance for unproven, research-grade risk. Pick one aging hallmark, one or two trackable markers, change one variable at a time, and judge it with a clinician over months. Be most skeptical of the dramatic animal stories - FOXO4-DRI, 5-Amino-1MQ - whose usage outruns their human evidence. The selector at the top narrows the field to your constraints, but the final call belongs with a clinician who knows your history. From here, the natural next reads are the Epitalon complete guide, best peptides for mitochondrial health, and how to vet peptide quality.

Sources

• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "The Hallmarks of Aging." Cell, 2013. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/23746838/
• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "Hallmarks of aging: An expanding universe." Cell, 2023. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/36599349/
• Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. "Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans" (Laron syndrome cohort). Science Translational Medicine, 2011. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/21325617/
• Fontana L, Partridge L, Longo VD. "Extending Healthy Life Span - From Yeast to Humans" (reduced IGF-1 signaling and longevity). Science, 2010. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/20395504/
• Baar MP, Brandt RMC, Putavet DA, et al. "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging" (FOXO4-DRI senolytic, aged mice). Cell, 2017. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/28340339/
• Khavinson VKh. "Peptides and Ageing" / Epitalon geroprotector cohort studies. Neuroendocrinology Letters / peptide gerontology literature, 2002-2003. Retrieved 2026-06-19. https://pubmed.ncbi.nlm.nih.gov/14523363/
• U.S. Food & Drug Administration. "Information about peptide drug products / compounding and safety communications." 2023-2025. Retrieved 2026-06-19. https://www.fda.gov/drugs/human-drug-compounding/information-about-peptide-drug-products
• ProtocolPlus. "Community goal-usage data: longevity" (goals/longevity.json). First-party app data, 2026. n ≈ 2,600 users pursuing longevity. Usage signal, not a clinical efficacy or lifespan ranking.